J&J To Acquire Ollin Biosciences for $2.2 Bn
Johnson & Johnson (J&J) has agreed to acquire Ollin Biosciences, a clinical-stage bio/pharmaceutical company focused on therapies for serious eye diseases, in a deal worth up to $3.3 billion ($2.2 billion upfront and $1.125 billion in milestone payments).
Ollin’s lead asset is OLN324, an investigational bispecific antibody in Phase III development designed to target two key pathways in retinal diseases, vascular endothelial growth factor and angiopoietin-2. It is being developed to treat conditions including wet age-related macular degeneration and diabetic macular edema.
Under the agreement, J&J will acquire Ollin for $2.2 billion upfront, with the potential for regulatory and commercial milestone payments up to approximately $1.125 billion. The transaction is expected to close before the end of 2026, subject to applicable regulatory approvals and customary closing conditions.
Separately, J&J will also enter into a development funding agreement with Blackstone Life Sciences, a private investment platform focused on the bio/pharmaceutical and life sciences sector, of the private equity firm, Blackstone, to support the Phase III clinical advancement of OLN324, contingent upon acquisition close.
Under that agreement, Blackstone will pay a total of $750 million to J&J over multiple years to fully fund the Phase III development of OLN324. In return, Blackstone will be eligible to receive certain regulatory and sales milestone payments as well as single-digit royalties.
Source: Johnson & Johnson and Ollin Biosciences

